

August 14, 2021

CHARLES SMITH

NEVADA STATE BOARD OF HEALTH
4150 TECHNOLOGY WAY | SUITE 300
CARSON CITY NV | 89706

I understand that you are considering mandating that all Nevada students be vaccinated against COVID-19 in violation of federal law. All COVID-19 vaccines are merely authorized, not approved, or licensed by the federal government; they are only Emergency Use Authorization (EUA). However, they are proven and effective treatments that are being regulated and suppressed.

Perhaps you might have missed this in the news: **The Loyola University backs down on COVID-19 vaccine requirement in the face of a federal lawsuit.** The university granted religious exemptions to a group of 11 students who objected to the abortion-tainted COVID-19 vaccines.

A PCR test has been the gold standard to determine whether or not someone has Covid, although its creator admitted it was not an intended diagnostic tool. The FDA pulled the EUA from them. In addition, the CDC has now announced that the PCR tests can't differentiate between Covid and Influenza. I have attached page 38 of the CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time PCR Diagnostic Panel as evidence that the CDC PCR tests are not accurate.

So while it is egregious that you will allow this to happen on our campuses, you may not have to answer to me or many other concerned parents and students, but I am putting you on notice that you cannot hide behind one-sided science. However, I am confident that either in this life or after, you will have to answer to Jesus Christ, who will judge the living and the dead. I implore you to allow religious and medical exemptions!

SINCERELY,

LISA FLEINER

"It is a fearful thing to fall into the hands of the living God." Hebrews 10:31 King James Version

- Inhibitors or other types of interference may produce a false-negative result. An interference study evaluating the effect of common cold medications was not performed.
- Test performance can be affected because the epidemiology and clinical spectrum of infection caused by 2019-nCoV is not fully known. For example, clinicians and laboratories may not know the optimum types of specimens to collect, and, during the course of infection, when these specimens are most likely to contain levels of viral RNA that can be readily detected.
- Detection of viral RNA may not indicate the presence of infectious virus or that 2019-nCoV is the causative agent for clinical symptoms.
- The performance of this test has not been established for monitoring treatment of 2019-nCoV infection.
- The performance of this test has not been established for screening of blood or blood products for the presence of 2019-nCoV.
- This test cannot rule out diseases caused by other bacterial or viral pathogens.

Conditions of Authorization for the Laboratory

The CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel Letter of Authorization, along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients, and authorized labeling are available on the FDA website: <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>.

However, to assist clinical laboratories using the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel (“your product” in the conditions below), the relevant Conditions of Authorization are listed below:

- Authorized laboratories using your product will include with test result reports, all authorized Fact Sheets available on the CDC website. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- Authorized laboratories using your product will use your product as outlined in the authorized labeling available on the CDC website. Deviations from the authorized procedures, including the authorized RT-PCR instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted under this authorization.
- Authorized laboratories that receive the commercially manufactured and distributed primer and probe sets identified as acceptable on the CDC website for use with your product, and are not able to obtain the authorized Human Specimen Control and authorized Positive Control for 2019-nCoV (NCoVPC) materials described in your product’s authorized labeling, may use appropriate materials identified as acceptable materials on the CDC website for use with your product. Authorized laboratories that receive your product will notify the relevant public health authorities of their intent to run your product prior to initiating testing.
- Authorized laboratories using your product will have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.